ArticleJSES international2026
High-dose extracorporeal shockwave therapy restores shoulder motion in adhesive capsulitis after a single session.
Article in JSES international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracorporeal shockwave therapy (ESWT) is widely applied to manage musculoskeletal disorders, including shoulder pathologies. However, the optimal therapeutic dosage for adhesive capsulitis (AC) remains unclear. This study aimed to evaluate the dose-response relationship of ESWT in patients with AC. Methods: In this randomized controlled trial, 48 patients with AC refractory to conservative management were assigned to receive a single session of either basic-dose (3,000 pulses) or high-dose (6,000 pulses) ESWT. Shoulder range of motion was assessed at baseline, immediately after treatment, and at 1, 2, 4, 8, and 12 weeks. Functional outcomes were evaluated at 12 weeks using the Constant Murley score. Subgroup analysis was performed based on baseline abduction (cutoff: 90°). Results: At 12 weeks, the high-dose group demonstrated significantly greater improvements than the basic-dose group in forward flexion ( Conclusion: High-dose ESWT provided significantly enhanced recovery of shoulder range of motion and function compared with a basic-dose protocol in patients with AC. These findings support a dose-response relationship; however, results should be interpreted as short-term outcomes given the 12-week follow-up and absence of a control group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.